Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Medtronic plc
Medtronic plc News
Medtronic plc Quantitative Score
About Medtronic plc
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Medtronic plc Earnings & Revenue
Medtronic plc Financials
Table Compare
Compare MDT metrics with: | |||
---|---|---|---|
Earnings & Growth | MDT | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | MDT | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | MDT | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | MDT | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Medtronic plc Income
Medtronic plc Balance Sheet
Medtronic plc Cash Flow
Medtronic plc Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
Metrics | Score |
---|---|
Discounted Cash Flows | Buy |
Return on Equity | Buy |
Return on Assets | Buy |
Debt/Equity Ratio | Sell |
Price/Earnings Ratio | Strong Sell |
Price/Book Ratio | Neutral |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Medtronic plc Dividends
Yield (TTM) | Dividend (TTM) | |
---|---|---|
Infinity% | 2.7800 |
Payment Date | Dividend | Frequency |
---|---|---|
2024-10-11 | 0.7 | Quarterly |
2024-07-12 | 0.7 | Quarterly |
2024-04-12 | 0.69 | Quarterly |
2024-01-12 | 0.69 | Quarterly |
2023-10-13 | 0.69 | Quarterly |
Medtronic plc Valuation
Project future cash flows and get the intrinsic value per share.
Historical Market Cap
Shares Outstanding
Medtronic plc Executives
Name | Role |
---|---|
Mr. Geoffrey Straub Martha | Chairman of the Board & Chief Executive Officer |
Mr. Gregory L. Smith | Executive Vice President of Global Operations & Supply Chain |
Mr. Brett A. Wall | Executive Vice President & President of Neuroscience Portfolio |
Mr. Sean M. Salmon | Executive Vice President & President of Cardiovascular Portfolio |
Dr. Kenneth E. Washington Ph.D. | Senior Vice President and Chief Technology & Innovation Officer |
Name | Role | Gender | Date of Birth | Pay |
---|---|---|---|---|
Mr. Geoffrey Straub Martha | Chairman of the Board & Chief Executive Officer | Male | 1970 | 3.56M |
Mr. Gregory L. Smith | Executive Vice President of Global Operations & Supply Chain | Male | 1964 | 1.76M |
Mr. Brett A. Wall | Executive Vice President & President of Neuroscience Portfolio | Male | 1966 | 1.75M |
Mr. Sean M. Salmon | Executive Vice President & President of Cardiovascular Portfolio | Male | 1965 | 1.68M |
Dr. Kenneth E. Washington Ph.D. | Senior Vice President and Chief Technology & Innovation Officer | 1960 | -- |
Medtronic plc Insider Trades
Date | 20 Aug |
Name | Marinaro Michael |
Role | EVP & President, Surgical OU |
Transaction | Disposed |
Type | F-InKind |
Shares | 2045 |
Date | 15 Aug |
Name | Corona Gary Louis |
Role | Interim CFO |
Transaction | Acquired |
Type | A-Award |
Shares | 8966 |
Date | 3 Aug |
Name | Corona Gary Louis |
Role | Interim CFO |
Transaction | Disposed |
Type | |
Shares | 0 |
Date | 31 Jul |
Name | Corona Gary Louis |
Role | Interim CFO |
Transaction | Disposed |
Type | |
Shares | 10164 |
Date | 29 Jul |
Name | Corona Gary Louis |
Role | Interim CFO |
Transaction | Disposed |
Type | |
Shares | 1540 |
Date | Name | Role | Transaction | Type | Shares |
---|---|---|---|---|---|
20 Aug | Marinaro Michael | EVP & President, Surgical OU | Disposed | F-InKind | 2045 |
15 Aug | Corona Gary Louis | Interim CFO | Acquired | A-Award | 8966 |
3 Aug | Corona Gary Louis | Interim CFO | Disposed | 0 | |
31 Jul | Corona Gary Louis | Interim CFO | Disposed | 10164 | |
29 Jul | Corona Gary Louis | Interim CFO | Disposed | 1540 |